Grant: Proof of Principle Program - Phase I
Université Laval
$160,000.00
Development of a treatment for Friedreich ataxia based on the administration of TALE proteins targeting the frataxin promoter.
FY 2012-13
Summary
Friedreich's ataxia is caused by a reduced expression of frataxin due to a longer GAA trinucleotide repetition in intron 1 of
this gene. A potential treatment for Friedreich's ataxia is thus to increase frataxin gene expression. The gene coding for
TALE proteins can be modified to produce proteins that attach specifically to a desired DNA sequence. We have already
produced 12 genes encoding proteins TALEFrat specifically targeting different sequences of 12 nucleotides, located in the
DNA region that controls the human gene frataxin expression. The TALEFrat genes were fused with an amino acid
sequence, called VP64, and we showed that it induced the expression of a gene located after the targeted sequence. The
first objective of our research project is to determine whether the TALEFrat/VP64 plasmids also increase frataxin in normal
and Friedreich patient fibroblasts. YG8 mouse is a model of Friedreich's ataxia in which the two murine frataxin genes have
been rendered nonfunctional. However, this mouse contains an additional gene containing the frataxin gene of a Friedreich
patient. We will therefore verify whether the TALEFrat/VP64 increase the expression of frataxin in fibroblasts from these YG8
mice. The experiences of this first objective will enable us to select the TALEFrat/VP64 most effective in culture cells. The
TALEFrat/VP64 does not normally penetrate in cells. However, these proteins can be fused with a sequence of amino acids
that allows it to enter cells. The second objective is to verify that the most effective protein TALEFrat/VP64 coupled with such
a peptide can enter in human and YG8 cells in culture and in YG8 cells following injection in the mouse blood. The third
objective is to verify whether the TALEFrat/VP64 administrated to YG8 mice induce the expression of frataxin and prevents
the development of symptoms of Friedreich ataxia in this animal model.
Department
Program
Proof of Principle Program - Phase I
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
268465
Name
Tremblay Jacques P
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Development of a treatment for Friedreich ataxia based on the administration of TALE proteins targeting the frataxin promoter.
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$160,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Cell Penetratin Peptide; Frataxin; Friedreich Ataxia; Gene Expression; Tale Protein
Abstract
Friedreich's ataxia is caused by a reduced expression of frataxin due to a longer GAA trinucleotide repetition in intron 1 of
this gene. A potential treatment for Friedreich's ataxia is thus to increase frataxin gene expression. The gene coding for
TALE proteins can be modified to produce proteins that attach specifically to a desired DNA sequence. We have already
produced 12 genes encoding proteins TALEFrat specifically targeting different sequences of 12 nucleotides, located in the
DNA region that controls the human gene frataxin expression. The TALEFrat genes were fused with an amino acid
sequence, called VP64, and we showed that it induced the expression of a gene located after the targeted sequence. The
first objective of our research project is to determine whether the TALEFrat/VP64 plasmids also increase frataxin in normal
and Friedreich patient fibroblasts. YG8 mouse is a model of Friedreich's ataxia in which the two murine frataxin genes have
been rendered nonfunctional. However, this mouse contains an additional gene containing the frataxin gene of a Friedreich
patient. We will therefore verify whether the TALEFrat/VP64 increase the expression of frataxin in fibroblasts from these YG8
mice. The experiences of this first objective will enable us to select the TALEFrat/VP64 most effective in culture cells. The
TALEFrat/VP64 does not normally penetrate in cells. However, these proteins can be fused with a sequence of amino acids
that allows it to enter cells. The second objective is to verify that the most effective protein TALEFrat/VP64 coupled with such
a peptide can enter in human and YG8 cells in culture and in YG8 cells following injection in the mouse blood. The third
objective is to verify whether the TALEFrat/VP64 administrated to YG8 mice induce the expression of frataxin and prevents
the development of symptoms of Friedreich ataxia in this animal model.
Competitiondate
201209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tremblay, Jacques P
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $160,000~ $0~